ARWR
Arrowhead Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
5.89 / 10
Netural
Capital flow assessment yields 7.97/10, denoting robust fund flow characteristics. Strengths in overall, block, Small, Medium, and Extra-large trends confront pressures from Large patterns, resulting in positive liquidity outlook. Professional analyst opinion suggests predominantly positive analyst sentiment, showing moderate confidence. Distribution pattern: Strong Buy(50.0%), Buy(16.7%), Neutral(33.3%) based on 6 research evaluations, supported by 3.82 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
17%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-07
InstitutionGoldman Sachs
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for ARWR?
- ARWR holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.89/10 (Netural).
